Table 4.

Adjusted ORs of VEGF polymorphisms according to gender and NSCLC histology

Male
Female
Adenocarcinoma (706 cases/638 controls)
Squamous cell carcinoma (285 cases/638 controls)
Adenocarcinoma (770 cases/820 controls)
Squamous cell carcinoma (158 cases/820 controls)
OR (95% CI)POR (95% CI)POR (95% CI)POR (95% CI)P
Genotypes
VEGF −460C/T
    TT1.01.01.01.0
    CT+CC1.14 (0.85-1.52)0.380.92 (0.61-1.39)0.691.29 (0.99-1.69)0.061.21 (0.73-2.01)0.47
VEGF+405C/G
    GG1.01.01.01.0
    CG+CC1.39 (1.07-1.81)0.010.98 (0.67-1.42)0.901.07 (0.84-1.36)0.580.75 (0.47-1.77)0.20
VEGF+936C/T
    CC1.01.01.01.0
    CT+TT1.11 (0.84-1.48)0.461.39 (0.92-2.09)0.110.94 (0.75-1.27)0.851.23 (0.76-2.00)0.40
Haplotypes*
Global test0.020.230.540.67
    CGC1.01.01.01.0
    TCC1.18 (0.95-1.47)0.141.09 (0.80-1.47)0.230.95 (0.75-1.21)0.671.09 (0.80-1.47)0.59
    TGC0.76 (0.50-0.98)0.040.95 (0.67-1.35)0.760.95 (0.72-1.16)0.470.95 (0.67-1.35)0.76
    CGT0.87 (0.56-1.35)0.531.13 (0.60-2.10)0.711.36 (0.86-2.16)0.191.13 (0.60-2.10)0.71
    TCT1.14 (0.69-1.90)0.611.32 (0.68-2.58)0.550.91 (0.56-1.46)0.681.32 (0.68-2.58)0.42
  • NOTE: Adjusted for age, gender, smoking status, pack-years of smoking, and years since smoking cessation (if ex-smoker).

  • * The combined haplotype frequencies <5% were not included in the analysis.